First-in-Human trial tests engineered immune cells against rare cancers
NCT ID NCT06083883
Summary
This is an early-stage study to test the safety and find the right dose of a new cell therapy for patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. The therapy involves giving patients specially engineered immune cells (called NK cells) from a donor, along with chemotherapy. The main goals are to see if the treatment is safe and if it can help shrink tumors in patients whose cancer has come back after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYNOVIAL SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.